Critical Care Pharmacotherapy

Bijay Thakur[1], Mansi Mistry[1]

[1] Department of Pharmacy Practice, Parul Institute of Pharmacy, Parul University, Vadodara, Gujarat, India.

CHAPTER INFO

Received 18/11/2025
Accepted 15/03/2026
Published 02/06/2026

Keywords:
Pharmacotherapy
Clinical Pharmacists
Vasodilation
Septic shock
Hemodynamic stability
Antimicrobial stewardship
Pharmacokinetics
Pharmacodynamics

Corresponding author:
Bijaya Thakur
vijaythakur4142341@gmail.com

ABSTRACT

Critical care, particularly treating critically ill patients, frequently undergoes immediate physiological changes that influence drug absorption, distribution, metabolism, and excretion. Pharmacotherapy is crucial in ensuring the safety and effectiveness of the administration of drugs in those with these conditions. Pharmacists help by personalizing medication prescriptions, keeping an eye on the level of sedation, and striking a balance between safety and effectiveness. Registered pharmacists are essential in critical care pharmacotherapy because they can modify drug regimens according to the physiological requirements of each patient. They maintain an important equilibrium between drug safety and efficacy in critically ill patients by continuously monitoring the amount of medication, adjusting the dose to maximize therapeutic impact, and minimizing side effects. Systemic vasodilation and compromised vascular tone cause severe hypotension in septic and vasodilatory shock. Vasoactive drugs play a crucial role in the management of critically ill patients because they maintain organ perfusion, restore hemodynamic stability, and enhance survival rates. For these reasons, they are essential to critical care pharmacotherapy. Individualized pharmacotherapy is essential in the management of viral illness. To maximize patient safety and ICU outcome, personalized pharmacotherapy and clinical pharmacy service are necessary in critical care to prevent medication errors, optimize drug therapy, and ensure safe, effective treatment. Pharmacokinetics and pharmacodynamics are improved by the technique involving therapeutic medication monitoring and continuous and prolonged infusion, which somewhat facilitates bacterial eradication while inhibiting resistance. In order to enhance outcomes for critically ill patients, critical care pharmacotherapy requires precise, evidence-based, and customized treatments. In healthcare, an extremely-risk ICU individual, pharmacotherapy ensures safety, evidence-based medicinal utilization through specific treatment, careful intake of vasoactive and antimicrobial medicine, and overall intervention that reduces avoidable mistakes. Pharmacist and their support staff members contribute an important part in enhancing outcomes for advances in the safety of treatment in critical care.

Introduction

In the late 1960s, clinical pharmacy began growing into a distinct profession. But it wasn't until several decades later that in field experienced significant developments. The past couple of decades have included major improvements in clinical pharmacy, primarily because of the increasing visibility of pharmacists as critical components of compassionate care for patients. Clinical pharmacy services are now important in boosting the importance of pharmacotherapy and improving the quality of life in all kinds of care settings. Specifically in the critical care unit (ICU), a clinical pharmacist becomes a vital member of the multidisciplinary team. Actually, they support in therapeutic decision making, medication safety, and the prevention of drug-related issues.

Finding out that these clinical pharmacy services are successfully reaching their primary goal, most significantly enhancing patient outcomes, is crucial as the area of healthcare delivery continues to transform. Comprehensive documentation and analytical instruments are essential to evaluate the beneficial effect of the chemist's intervention, particularly in highly critical conditions like the intensive care unit. The result of these assessments promotes the utilization of resources, validates the chemist's role within the critical care setting, the guides toward the development of new protocols.

Professions norms highlight the need of documentation. In compliance with the British Columbia Health professions Acts and other guidelines set forward by pharmacist have the responsibility to precises record essential clinical activities in the medical record of a patients. This involves writing down prescription clarification, consultation, counceling, suggestion, for treatment and medicated associated concern in the patient's treatment files. The ICU must be equipped to immediately and comprehensively keeps records of everything that happens, including consultation responses, therapeutic plan, hypersensitivity histories and medication adjustments, with the aim to assure effective stability of care and medical team responsibility.

Pharmacist in regular clinical work estimate the value of drugs related issues and their capacity to harm patient care when organizing documentation. All ICU patients at the Royal Columbian Hospital (RCH) in New Westminter, British Columbia, are reviewed; however, newly admitted or clinically unstable patients receive extra attention and documentation of pharmacist because they're more likely to have active and major medication related issues. Clinical safety is assured by such paperwork, that also matches the standards for accreditation and offers beneficial data for quality assurances process. By quickly writing an intervention in the patient's chart, caregivers can ensure efficient interaction and decrease the record duplication. [1].

Complex regimens of medications, increased risk of Medication Related Problems (MRPs), and Post Intensive Care Syndrome (PICS) have become prevalent among ICU survivors, all of them contributes to repeat remissions to the hospitals. Whereas ICU pharmacists emphasizing on maximizing acute drugs, ICU recovery clinics (ICU-RC) pharmacists tackle prolonged treatment difficulties after hospital discharges, such as inappropriate administration of ICU specific medicine or neglecting chronic prescription. Their service includes multidisciplinary medication management, instruction for patients, specialist consultation and reconciliation. Engaging pharmacist has been empirically proven beneficial for the safety of medications and performance. Unfortunately, ICU-RC service remains in limited availability so additional investigation must be done to compare how effective they are in comparison to conventional ICU Clinical pharmacy practices. [2].

Roles and responsibilities of clinical pharmacist in critical care

Tough patient report: Critical care setting might have multiple kinds of condition that have both acute and chronic, which makes therapy management more complicated.

Better survival rates: Researches studies have shown as obvious connection between higher pharmacist involvement with critical care units and reduces mortality rates.

Medication Reconciliation: Pharmacist makes certain that pre-admission and hospital medications are effectively reconciled by decreasing omission and duplication mistakes.

Drug Interaction Management: The access and prevent unwanted drug-disease interactions and drug-drug interaction.

Ward Round Participation: Pharmacist vigorously promote safer, scientifically proven medication therapy by participating part in the multidisciplinary in ICU rounds.

Cost Reduction: Pharmacist intervention lessen expenditures by managing formularies, reducing unwanted prescription, and optimizing dosages.

Advancement of Quality: All pharmacist intervention focus on improving pharmaceutical safety, efficacy and medical result.

Education and Training: Pharmacists advices healthcare professionals, nurses, and residents on proper administration of drugs.

Drug Use Evaluation: They evaluate and ensure appropriate drugs use with adherence to hospital rules and regulation.

Emergency Response: Having pharmacists available for code blue and cardiac arrest cases enhances adherence to ACLS protocols and minimize death.

Thromboembolism prophylaxis: Pharmacist lower the risk of thromboembolism consequences by assuring adherence to preventative schedules.

CRRT Dose Modification: pharmacist assist people getting continuous renal replacement therapy (CRRT) with dose modification in order to maximize their therapy.

Adverse Drug Event Prevention: pharmacist have a critical role in determining, avoiding, and documenting adverse drug event in ICU.

Compliances and Recording: They promote adherence to clinical recommendation and assure accurate medication history recording.

Participation in Clinical Research: Pharmacists take part in research studies taken out in ICU and assist in creating treatment procedure.

Tele-Pharmacy Support: Remote ICU or tele-pharmacy services ensure regular monitoring of medications during off-peak hours.

Advocacy for Patients Safety: Pharmacists act like mediators between patient and prescriber so that medication are uses correctly.

Clinical and Economic Achievement: Their presence significantly decrease hospital stays, minimize prescription expenses, and improve overall treatment. [3].

Rational use of high-risk medications

Critically ill patients in the ICU need and individualized and constant surveillance for medication because of their numerous organ abnormalities and uncontrolled health condition. When extremely risk medication with therapeutic window are given to the patients, handling medication becomes more complicated and precise administering along with surveillance must be performed. Clinical pharmacist participates in an extremely important part in verifying that medication is used approximately and minimizing serious adverse drug reaction in hospital and critical care center.

The clinical pharmacist is actively involved in patient care rounds, evaluate therapeutic charts, and investigate for potential problems associate with drugs as an essential member of the ICU team. They examine for drugs medication interaction, analyze therapeutic amounts of drugs, and maintain appropriate dosage medications. Pharmacist specialized with reconciliation of medication in addition to maintain therapy consistency and preventing missed prescription or duplicated medication during treatment changes. The strategics they utilized significantly improve patient safety, reduce hospitalization in ICU, along with minimize the effectiveness of treatment.

High risk medications need to be used carefully in an ICU to prevent complication and achieve successful treatment. Sedation evaluation for example the Richmond Agitation Sedation Scale (RASS) should be implemented to precisely adjust the doses of sedative and analgesics such as medication midazolam, propofol, dexmedetomidine and fentanyl with the objective to prevent the respiratory depression and excessive sedation. Regular sedation breaks minimize tolerance and addition. Antibiotics needs to be used carefully via antimicrobial stewardship approaches such dose effectiveness, culture-based selection, and de-escalation in order to decrease resistance to antibiotics. Vasopressors and inotropes that consist of norepinephrine, dopamine, and vasopressin have to be adjusted to maintain Mean Arterial Pressure

(MAP) while limiting adverse effect such as arrythmias or tissue ischemia, The pharmacist monitors proper concentration compatibility, and safe administration. [11,12,13,14]

The pharmacological mechanism, recommended dosage s suggestions, and potential adverse reactions of important categories of medication that are frequently used in the ICU must be examined in order to provide an extensive understanding of pharmacotherapy in critical care. The clinical significance, monitoring protocols, and safety issues of sedative vasopressors and antibiotics are emphasized below.

Sedation

When it comes to control agitation and anxiety carried on by situation including pain, delirium, dyspnea, and mechanical ventilation, sedations are commonly used in the ICU. Effectively medical care may be easier by appropriate sedation, sedation, which further optimizes patient comfort and safety. Inappropriate or excessive use of, however, may end up in the delirium, long term cognitive impairment and continual mechanical ventilation. As in outcome, sedation should always be clearly advice, with proper drug selection and clear treatment goal.[4]

Arousal monitoring

Several ICU arousal scales are accessible for use in individual patient goal directed therapy. The Richmond arousal scale is the most widely employed. Such scale can serve as therapeutic aim when applied properly, which may result in decrease sedative medication and less time of mechanical ventilation. Arousal assessments, however is an element of all critically unwell patients neurological screening should not be considered correlate with the application of medication for sedation. When a patient is taking Neuromuscular blocking drugs, it is extremely important to remember that the arousal scales aren't relevant. In these circumstances, the Bispectral Index monitoring should be included in consideration. [4]

Selection of sedative regimen

Since no sedative on the market now meets all of these criteria, a suitable ICU sedative should be relatively cheap, have no active metabolites, generate little respiratory depression, have shorter half life that is sensitive to context, and be switched out regardless of organ function. Benzodiazepine, propofol and dexmedetomidine and often other drugs; ketamine, clonidine and volatile anesthetics, and neuromuscular blockers are adjuncts. Since sedation duration is strongly correlates with chronic mechanical ventilation, the lowest effective doses, daily sedation interruption and limit to infusion period are encouraged. Evidence is gathering that benzodiazepine are used to minimized and that analgosedation technique such as propofol, dexmedetomidine or other substances should be used replacement in order to boost ICU improvement.[4]

Propofol

Propofol is a diisopropylphenol anesthetic that behaves as a GABA agonist. Due to rapid absorption (1-2) minutes and shorter duration (2-8) minutes, it is frequently employed to induce unconscious patients in intensive care unit. A continuous infusion of 25 ug/kg/min is given after an IV bolus of 40-100mg. Due to its wide distribution volume and shorter half life, propofol can bee quickly emerges through redistribution and is most helpful in people with hepatic or renal failure. However, tissue saturation result from high dose or continued infusion, and thus metabolic clearance is necessary for emergencies.

Hypertriglyceridemia, myocardial depression, respiratory depression and hypotension from vasodilation are typical side effects. Propofol Infusion Syndrome (PRIS) is a dangerous side effect that comes along with dose exceeding 75 ug/kg/min or infusion lasting more than 48hrs, especially in scenario of critical illness. PRIS has increasing fatality rate and appears as several lactic acidosis and rhabdomyolysis. Lactate, pH, CK, triglycerides, and ECG alteration (Brugada pattern) must all be monitored, and if any of these are observed, the medication must be stopped as soon as possible. [4]

Dexmedetomidine

Dexmedetomidine is an alpha 2 agonist which binds on receptors in spinal cord and locus coeruleus leading to dizziness and fairly low analgesia any of its primary advantage, it doesn't greatly hamper lung's function, which render it helpful for ICU patients especially those requiring mechanical ventilation. An infusion of 0.2-0.7 ug/kg/hr, is the usual dosage, and bolus dosage tent to be avoided because of increased change of hypertension. Bradycardia, hypotension are the most common side effect, especially when taking larger dosages (up to 2ug/kg/h. Because of its hepatic metabolism, Dexmedetomidine requires a dose reduction in case of liver dysfunction but in condition of renal impairment.[4]

Benzodiazepines

Benzodiazepines, that work as GABA agonists, are frequently utilized as ICU sedatives. Examples of such drugs includes midazolam, lorazepam, and diazepam. When lorazepam is an exception, it contains propylene glycol which may result in metabolic acidosis. Most are metabolized by liver to active metabolites, which prolonged drowsiness, particularly in renal failure. Benzodiazepines have been associated with higher brain dysfunction, ventilation duration and ICU stay leading to reduce used in favor of propofol and dexmedetomidine. Nonetheless, they seems to be the first choice for seizures and delirium tremens. According to WHO, midazolam dose is 0.02-0.1 mg/kg for IV bolus and for infusion is 0.02-0.1 mg/kg/hr titrated to sedation targets and its major side effect are Respiratory depression, hypotension, if prolonged sedation in renal /hepatic impairment and sometimes change of delirium risk. [4]

Vasopressors

Vasopressor are typically prescribed for regulating adequate circulation to the tissue in the management of sudden hypotension and severe shock. They're pharmacological medications which elevate arterial blood pressure by increasing systemic vascular resistance through constriction of the arteries, primarily by activating alpha-adrenergic receptors or the hormone vasopressin.[5]

Biomarkers to guide vasopressor selection

By customized therapy, biomarkers that are predictive may improve the protection and efficacy of vasopressors in vasodilatory shock. In order to identify the most suitable responders, investigators are searching biomarkers involving plasma protein levels, medication concentrations, RNA expression patterns and quick SNP genotyping. Norepinephrine selection might be impacted by B2- adrenergic receptors SNPs, which are related to elevated death rate in septic shock. Vasopressin response might be determined by plasma angiopoietin-2 level and genetic variations in leucyl/ cystinyl aminopeptidase (LNPEP) and AVPR1a which impact vasopressin metabolism and vascular permeability. In addition, biomarkers associated with the RAAS and SNPs in the angiotensin-II receptors- associated protein (AGTRAP) are correlated with lower outcomes and might suggest that angiotensin-II medicine are recommended.[6]

Vasopressin (antidiuretic hormone)

Strong vasoconstrictor vasopressin generally focuses on vascular smooth muscles via V1a-receptors. It is even more efficacious in acidemia, unlike a- adrenergic agonists, when catecholamine response reduces. To improves MAP and enable catecholamine -sparing effect by correlating vasopressin deficiencies in shock, low, fixed dosages (0.03-0.04 U/min) are advised. Only refractive vasodilatory shock can be effectively treated at higher doses (up to 0.1 U/min) that can rise MAP additionally due to the risk of mesenteric ischemia. Identical to norepinephrine, vasopressin promotes MAP while having a lower heart rate and cardiac output. Particularly useful for right ventricular failure, it can reduce pulmonary vascular resistance and enhance system vascular resistance. Although there can be no overall mortality reduction in septic shock, clinical investigation like vasopressin and septic shock trial (VASST) provide advantage in

patient taking corticosteroids and milder form of shock. Vasopressin is safe and useful adjuvant, not a first-line treatment, when norepinephrine along is insufficient or produces arrythmias.[5]

Norepinephrine (First line agent)

Receptor agonist with mild to moderate B1 activity and negligible to B2 effect. Its hemodynamic reaction, which increase Systemic Vascular Resistance (SVR) & Mean Arterial Pressure (MAP), primarily triggered by a1- mediated vasoconstriction. In the meantime, B1 stimulation provides sufficient inotropy that help with regulating CO. Higher dose can elevate CO in the patient who respond well to preload, whereas excessive afterload can reduce CO in the patient with cardiac disease. Although somewhat less potent than epinephrine, norepinephrine is 100 times more potent than dopamine and 3-5 times stronger than phenylephrine when it comes to elevating Mean Arterial Pressure (MAP). Refractive shock has no maximum amount or no limit, but dosage exceeding 0.5-1ug/kg/min are considered excessive. Reflex bradycardia may be brought on by MAP rise, but tachycardia is possible at greater dosages. All the three of the most common types of shock – septic, cardiogenic, and undifferentiated shock the substance norepinephrine is the first line vasopressor for severe hypotension. When no other vasopressor has been found in clinical trials to produces better results, current guideline prefers norepinephrine (with dopamine when necessary) above dopamine, even in the cases of cardiogenic shock.[5]

Epinephrin (Second line /Refractory shock)

Due to its better beta2 activity than norepinephrine and its stronger alpha1 and beta1-receptor agonist properties, epinephrine is a potent inotrope that is nearly 100 times more potent than dobutamine and dopamine. Heart rate (HR) and cardiac output (CO) are induced by modest dosages (0.01-0.1ug/kg/min) through B1/B2 stimulation. Low dose epinephrine minimizes tachycardia and improves MAP, CO, SV following heart surgery when compared to dobutamine. To improve MAP and cardiac index, epinephrin is added to norepinephrine when it is administered to septic shock patient whose MAP is less than 70 mmHg. Alpha 1 mediated vasoconstriction cause strong vasopressor effect at higher dose (>0.1ug/kg/min). Usually employed as a second line treatment, it has no upper limit on dosage and can be used in the event of refractive shock.[5]

Dopamine (not preferred)

Dopamine binds B1- dopaminergic, and at greater amount a1-receptors. This vasoactive agent is dose dependent. Clinical studies show little advantage in avoiding AKI, however dopaminergic receptor activation promotes renal and splanchnic vasodilation with natriuresis and transitory increase in production of urine at very small “renal dose” (<4ug/kg/min). Moderate inotropes dosage of B1 stimulation (4-10ug/kg/min) increase HR, SV, CO and MAPs. Usually, CO peak between 4 and 6 ug/kg/min, and dosage escalation may be avoided by tachycardia and raising SVR. High vasopressor dose (>10ug/kg/min) are the main cause of a1-activation, which elevates MAP through vasoconstriction without additional CO improvement and can be cause pulmonary congestion. Dopamine is no longer recommended as the first line vasopressor in septic shock unless the patient has low risk of tachyarrhythmias and relative bradycardia. (5)

Phenylephrine (Pure vasoconstrictor)

Phenylephrine is a selective a1-receptor agonist that enhances the arterial and venous tone without B1/B2 activity. It supports CO in warm distributives shock when baseline cardiac function is satisfactory. Its 20 minutes duration allows for a bolus dosage (0.1-0.5mg every 5-15 minutes) for abrupt hypotension. An infusion of 1.5-2ug/kg/min may be delivery repeatedly to avoid tissue ischemic and vasoconstriction. For short term stabilization, peripheral administration is an option. Compared to norepinephrine it supplies MAP that is equal having lower HR and CO. phenylephrine is nor usually suggested in septic

shock; it is reserved to people who developed norepinephrine induced arrhythmias or lasting hypotension with increased CO. [5]

Dobutamine

Dobutamine is a B1-agonist inotropes that improves myocardial contractility, CO and SV. It has B2 and a1-activity is also moderate in nature. An IV infusion of 2-20ug/kg/min is the regular dosage. A lower dose (lesser than or equal to 5ug/kg/min) increase CO with little tachycardia, while higher dose (>10-15ug/kg/min) may cause considerable tachycardia and decrease diastolic filing time. SVR is partially lowered by the MAP response, which make it reliant on baseline CO and SVR. In cardiogenic shock (low CO and high SVR), dobutamine elevates MAP, but it may worsen hypotension in vasodilatory shock (low SVR). Its rapid onset and short half-life (less than 2 min) permit immediate titration. It is additionally recommended in septic shock when organ perfusion becomes impaired even after volume and MAP have been restored, and in acute MI with hypoperfusion and hypotension. Long term administration of B-blockers can cause tachyphylaxis and their effectiveness is reduced.[5]

Antibiotics

Antibiotics stewardship program in ICU

By implementing an Antimicrobial Stewardship Program (ASP) that produces the greatest therapy, decrease the uses of broad- spectrum antibiotics, minimizes infection and colonization by multidrug-resistance bacteria (MDRB), reduces adverse event related to antimicrobial, and lower healthcare associated costs without increasing mortality, the ICU may substantially enhance antimicrobial application. The ESCMID study group on antimicrobial stewardship program defines ASP as "a coherent set of action that promotes the responsible use of antimicrobials to ensure sustainable access to effective therapy to all who need them''. ASP could be considered as a designed quality improvement program which involves evidence-based intervention, clear targets and indicators, ongoing evaluation with prescriber's opinion and developing capacity strategies and systematics approaches to identify the close gap in quality. An ICU leader with expertise in antimicrobial therapy must oversee ASP operation to guarantee their successful execution. ASP intervention can be divided into 3 main categories;

Examples of collaborative or enhancement measures include prescriber education, the implementation of guideline, pharmacokinetic/ pharmacodynamic optimization and audit feedback;

Examples of structure measures includes computerized decision support tools, rapid diagnostic systems, antibiotic surveillance, and interdisciplinary collaboration among ICU clinicians, pharmacist, microbiologist and infection control staff.

Examples of restrictive measure control of formulary restriction, automatic stop order and prior approval by an infection disease specialist.

An adequate ASP should be tailored for the ICU including organization structure, MDRB prevalences, local prescribing culture and available resources, it must supply timely introduction of antibiotics during period of severe illness. Implementation science principle can be used to lead coordinate attempts for future improvements in antibiotic uses, resistance prevention, and patient outcomes through identifying barrier and facilitators. [8]

Right molecules but avoided the wrong doses

Determining the right antibiotics dosage requires knowledge about the infection sites and the bacteria's minimum inhibitory concentration (MIC), but there is a typical no instruction on how to adjust dosages. In case of culture negative sepsis, it is usually suggested to employ does the target organism with the greatest potential MICs. Luckly underdosing is widespread among critically sick patients; nearly one in

six patients receiving beta lactam antibiotics do not achieve minimum effective doses, and may do not reach optimal level for killing bacteria. This might compromise the effectiveness of treatment during the critical initial phases of therapy. Establishing the ideal antibiotics concentration becomes particularly important for those who are critically ill during the few hours of treatment, when maximum therapeutics is wanted. The physical and chemical properties of the medicament (hydrophilic or lipophilic nature), details about the patients, route of administration and the uses of organs support system like renal replacement therapy (RRT) or extracorporeal membrane oxygenation (ECMO) all contribute to dosage optimization, so there is no one solution that works for everyone. Although it cannot be directly measured in critically ill patients, and the volume of distribution (Vd) plays as essential roles for determining appropriate antibiotics dosages. Regardless of whether intermittent or continuous infusion is used, people with an elevated Vd – such as those with positive fluid balance need higher loading dose to quickly achieve therapeutic concentrations especially when utilizing hydrophilic antibiotics. Additionally, even when using prescription that will be primarily eliminated by the kidney, their initial doses should not be decreased due to kidney function. In case if AKI or increased renal clearance (greater than or equal to 130 mL /min/1.73metre square, adjustment to doses for maintenance therapy are essential because many ICU antibiotics undergo renal clearance. For the purpose to preserved effective levels, this latter condition frequently results in lower antibiotics exposures, demanding greater maintenance doses.

Pharmacokinetics /pharmacodynamics (PK/PD) optimizes the dosages, which is a process consisting of three stages informed by models and upgraded through therapeutic drug monitoring (TDM), is dependent on this consideration. Greater precision and personalized antibiotic dosage techniques in the intensive care unit are currently possible because to complex software tools and collaboration with prescribed medication surveillance systems. [8]

Prolonged or continuous infusion of beta lactam antibiotics in critically ill patients

Recent investigation points out the increasing trails supports for continuous or prolonged beta lactam antibiotics infusion in critically unhealthy patients. While previous published meta-analyses, conduct before 2010 fail to show any noticeable benefits, recent ones, involving information collected from 13 Randomized Collected Trails (RCTs), have shown significant improvement in critical cure rates among septic ICU patients and those at high-risk deaths.

Continuing infusion boosted the clinical cure rates in septic patients Relative Risk(RR)1.194,95%CL[1.015-1.405]) and in patients with severe illness Acute physiology and Chronic Health Evaluation (APACHE II greater than or equal to 20 or Simplified Acute Physiology Score (SAPS II) greater than or equal to 52, RR 1.162[1.042-1.296]) in the updates analysis, despite the mortality rates remain statistically unchanged. Regular infusion raised cures rate in patients with APACHE II >15 OR 3.45[1.08-11.01] with no changes in mortality, as reported by gram negative bacteria nosocomial pneumonia. Following the specific meta-analysis on severe sepsis, patients with APACHE II greater than or equal to 22 displayed an impressive rise in clinical cure (RR1.40[1.05-1.87]) although there were no significant variations in death (RR 0.79[0.53-1.01], previous investigation also demonstrate beneficial for patients with APACHE II greater than or equal to 15 showing improved cure (RR1.266[1.06-1.50]) and lower death rates (RR 0.63[0.48-0.81]).

Several clinical trials further corroborate these finding. In one RCT with piperacillin/tazobactam, the overall 14-day mortality rate similar (11.5% vs,15%); however, prolonged infusion significantly decreased mortality in patients with APACHE II greater than equal to 29.5 (12.5% vs 40.5%, P=0.01). According to a different cohort study, individuals with APACHE II greater than equal to 17who received continuous dosage exhibited lower 30-days readmission and inpatient death rates (OR 0.20 [0.07-0.57]). With 30-day survival (73% vs. 25%) and clinical cure (73%vs.35%) for SOFA greater than equal to 9, the Defining Antibiotic Level in Intensive care (DALI) group similarity confirmed batter outcomes.

In conclusion continuous or prolonged infusion of beta lactam antibiotics significantly boost clinical recovery rates in critically ill individual, particularly in those with high APACHE II or Sequential Organ Failure Assessment (SOFA)scores, however in consistent reduction in mortality remains inconsistency. It is presently incapable to developed a consistent severity criterion due to differences in evaluation cutoffs and study setting. [7]

Medication error prevention in critical care

Medication errors is produced by medical professionals, especially adverse drugs events have been thoroughly investigated over the years and poses the serious hazards for consumers safety. Injuries connected with unfavorable medical event were originally defined by the Harvard Medical Practice study, one of the first and most important research in this field. The groundbreaking work sparked a number of additional investigation examining the frequency, causes, and preventability of such experiences in other medical facilities. The Adverse Drug Prevention group's finding which showed that the rate of ADEs was 11.5 per 1000 patients days and 6.1 per 100 hospital admissions, aroused high security concerns. ADEs most frequently occurring in medical ICUs with the prevalence of 19.4 per 1000 patients days. This is probable due to the severity of illness, the difficulty of the management and the application of multiple hazardous drugs. However, it is crucial to keep in mind that the most ADE research depends on voluntary reports and chart reviews, which is typically underestimate the actual amount of error. In a famous study, investigators discovered a high prevalence potential ADEs responses particularly the drugs therapy distribution and administration periods. They also noticed that the prescription (77%) and administration (23%) period accounted for the bulk of unnecessary ADEs.

In order to prevent the prescription errors, Computerized Physician Order Entry (CPOE) systems were developed with the objectives of increasing legibility. While CPOE systems have decreased some types of pharmaceutical errors, they have additional created new sources of error. Problems such as fragmented display screen, separation of clinical task, duplicate drugs orders and entry of incompatible pharmaceutical have occasionally led to double dosage or incomplete therapy orders. Research revealed 483 clinically significant ADEs out of 937admission in highly computerized hospital settings-an incredible 52 ADEs per 100 admissions. On these, 22% deserved both monitoring and intervention,32% needed intervention only,11% required monitoring just, and 95 cause major damage. The administration step came in second at 13% with the ordering stage composing 61% all the ADEs. Multiple investigation has found that ADEs are still occasionally recognized and recorded, which raise the likelihood that the cases reported are just the "tip of the ice berg". A follow up study found that 37% of ADEs were not preventable, 83% of clinically significant medication error were prospective ADEs and 17%of ADEs were avoidable. One of the most frequently cited underlying causes of such medication errors was prescribers lack of correct pharmacological expertise, along with poor communication and system level workflow gaps in critical care settings. All things considered, these studies demonstrate how difficult it is to guarantee medicinal products safety in ICU. While some procedures have been enhanced by technological solution such as CPOE, minimizing ADEs and increasing patient's outcomes require ongoing vigilance, multidisciplinary cooperation and education. [9]

Causes of medication errors in critical care

Medication errors in critical care are caused by a combination of human, systemic, and environmental factors. An ICU is tricky and hectic environment with potentially dangerous drugs, frequent drugs adjustment and critically ill people who have numerous diseases. Error may occur at any phase of the medication use process, including prescription, dispensing, preparation, administration and monitoring.

Human related factors: The human component are crucial. Fatigue, stress, time, constraint, and excessive workload all affect the judgement and focus of health care workers. Misunderstanding between

nurses, pharmacists, and physicians increase the likelihood of transcribing or interpretation errors, particularly during handovers or verbal orders. Poor pharmacological knowledge, wrong calculation or failing to considered hepatic or renal function can also lead to inappropriate dose.

System related factors: Examples of system related causes include poorly designed workflow, a lack of standardized treatment methods, and lack of safety checks. Occasionally disorganized handwriting or lack of documentation may contribute to errors in prescriptions. Although automated technique like automated Physician Order Entry is useful, error in software, duplicated order or incorrectly entered information could end up in new problems.

Environmental related factors: Environmental related factors such as noise, interruption, and shortage of staff all lead to medication errors. The usage of several infusion pumps, related-looking and sounding drugs and identical packaging complicated drugs identification even more, particularly in scenario of emergency.

Roles of clinical pharmacists in medication error prevention in critical care

Clinical pharmacist has a crucial role for enhancing medication safety and preventing error in critical care setting. In the ICU a highly dynamic environment where patients regularly receive various high-risk drugs. Precise drugs therapy is crucial, in this situation clinical pharmacist act as medication specialists, ensuring that every drug prescribed, manufactured, and administered is safe, effective and appropriate for the patient's condition. They examine prescriptions for correct doses, drug interaction, allergic and organ's function component like hepatic and renal impairment as part of their daily ward rounds. Pharmacists are also on duty for therapeutic drugs monitoring (TDM), particularly among drugs with a narrow therapeutics index, in order to guarantee optimal plasma level while avoiding toxicity.

In antimicrobial stewardship programs, pharmacists monitor responsible consumption of antibiotic to prevent side effect and resistance to drugs. They also essential in educating medical professional and nursing personnel about safe drugs administration method, possible adverse effect and best practices. By introducing computerized order input system, schedules, and standard operating procedure, they minimize prescription and administration mistakes. Clinical pharmacist also reviews prescription mistake data, identify repeats trends, and established preventive measure to improves the overall safety system. They develop hospital regulations, conducts, audits, and provide continuous training to ICU staffs among other responsibility too. All things considered, clinical pharmacist participation in critical care optimizes patient's outcomes, minimize hospital costs, and creates a culture of safety and accountability among healthcare providers as well as reducing prescription error. [3]

Clinical Significance and Application of Critical Care Pharmacotherapy Domains

The presented table provides a comprehensive overview of the essential domains within critical care pharmacotherapy, emphasizing the complexity and dynamic nature of drug therapy in critically ill patients. Due to significant physiological alterations, including changes in organ function and hemodynamic status, pharmacokinetic and pharmacodynamic parameters are often unpredictable in the intensive care unit (ICU). This necessitates individualized therapeutic approaches, including dose optimization, therapeutic drug monitoring, and continuous clinical assessment to ensure maximum efficacy while minimizing the risk of toxicity. In addition, the table highlights key therapeutic areas such as sedation management, hemodynamic support, and antimicrobial therapy, all of which require precise titration and vigilant monitoring. The use of high-risk medications, including sedatives and vasopressors, demands strict adherence to evidence-based protocols to maintain patient stability and prevent complications such as delirium, arrhythmias, or organ dysfunction. Furthermore, antimicrobial

stewardship programs and optimized infusion strategies play a critical role in improving clinical outcomes while reducing antimicrobial resistance and healthcare costs.

Table 1: Core Therapeutic Areas in ICU Pharmacotherapy and Their Impact on Clinical Outcomes

Overview of Key Components in Critical Care Pharmacotherapy

Domain	Key Elements	Clinical Role of Pharmacist	Impact on Patient Outcomes
Pharmacokinetics & Pharmacodynamics (PK/PD)	Altered absorption, distribution, metabolism, elimination in ICU patients	Dose adjustment, TDM, monitoring organ function	Optimizes efficacy, reduces toxicity
Sedation Management	Use of propofol, dexmedetomidine, benzodiazepines; RASS monitoring	Sedation scoring, dose titration, preventing over/under sedation	Reduces ventilation time, prevents delirium
Hemodynamic Support (Vasopressors/Inotropes)	Norepinephrine, vasopressin, dopamine, dobutamine	Dose titration, monitoring MAP, drug compatibility	Maintains organ perfusion, improves survival
Antimicrobial Therapy	Broad-spectrum antibiotics, PK/PD optimization, MIC-based dosing	Antimicrobial stewardship, de-escalation, culture-guided therapy	Reduces resistance, improves cure rates
Therapeutic Drug Monitoring (TDM)	Narrow therapeutic index drugs (e.g., vancomycin, aminoglycosides)	Monitoring plasma levels, dose individualization	Prevents toxicity, ensures therapeutic levels
Medication Error Prevention	Prescription, dispensing, administration errors	CPOE implementation, medication review	Enhances patient safety, reduces ADEs
Medication Reconciliation	Transition of care (admission, ICU transfer, discharge)	Identifying omissions, duplications, interactions	Prevents DRPs. improves continuity of care
High-Risk Medication Management	Sedatives, anticoogulants, vasopressors	Risk assessment, monitoring adverse effects	Minimizes complications and mortality
Multidisciplinary Collaboration	ICU rounds, decision-making with physicians and nurses	Clinical recommendations, therapy optimization	Improves clinical outcomes and teamwork
Antimicrobial Stewardship Program (ASP)	Guideline implementation, audit, restriction policies	Rational antibiotic use, education	Decreases MDR resistance, lowers costs
Continuous/Prolonged Infusion Strategies	Beta-lactam antibiotics infusion optimization	PK/PD-based dosing strategies	Improves clinical cure rates
Post-ICU Care (ICU-RC)	Long-term medication management	Follow-up, patient education, reconciliation	Reduces readmission, long term complications

Importantly, the integration of clinical pharmacists into the multidisciplinary ICU team is a central component reflected across all domains. Pharmacists contribute significantly through medication reconciliation, identification of drug-related problems, prevention of medication errors, and implementation of safety systems such as computerized physician order entry. Their involvement ensures a patient-centered, safety-focused, and outcome-driven approach to therapy, ultimately enhancing survival rates, reducing hospital stay, and improving overall quality of care in critically ill patients.[12]

Bibliography

1. Ho, C. K., Mabasa, V. H., Leung, V. W., Malyuk, D. L., & Perrott, J. L. (2013). Assessment of clinical pharmacy interventions in the intensive care unit. The Canadian Journal of Hospital Pharmacy, 66(4), 212–218. https://doi.org/10.4212/cjhp.v66i4.1267
2. Mohammad, R. A., Eze, C., Marshall, V. D., Coe, A. B., Costa, D. K., Thompson, A., Pitcher, M., Haezebrouck, E., & McSparron, J. I. (2022). The impact of a clinical pharmacist in an interprofessional intensive care unit recovery clinic providing care to intensive care unit survivors. JACCP, 5(10), 1027–1038. https://doi.org/10.1002/jac5.1671
3. Arredondo, E., Udeani, G., Horseman, M., Hintze, T. D., & Surani, S. (2021). Role of clinical pharmacists in intensive care units. Cureus, 13(9), e17929. https://doi.org/10.7759/cureus.17929
4. Pandharipande, P., Hughes, N., & McGrane, N. (2012). Sedation in the intensive care setting. Clinical Pharmacology Advances and Applications, 4, 53. https://doi.org/10.2147/cpaa.s26582

5. Jentzer, J. C., Coons, J. C., Link, C. B., & Schmidhofer, M. (2014). Pharmacotherapy Update on the use of vasopressors and inotropes in the intensive care unit. Journal of Cardiovascular Pharmacology and Therapeutics, 20(3), 249–260. https://doi.org/10.1177/1074248414559838
6. Russell, J. A., Gordon, A. C., Williams, M. D., Boyd, J. H., Walley, K. R., & Kissoon, N. (2020). Vasopressor therapy in the intensive care unit. Seminars in Respiratory and Critical Care Medicine, 42(01), 059–077. https://doi.org/10.1055/s-0040-1710320
7. Guilhaumou, R., Benaboud, S., Bennis, Y., Dahyot-Fizelier, C., Dailly, E., Gandia, P., Goutelle, S., Lefeuvre, S., Mongardon, N., Roger, C., Scala-Bertola, J., Lemaitre, F., & Garnier, M. (2019). Optimization of the treatment with beta-lactam antibiotics in critically ill patients—guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique—SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation—SFAR). Critical Care, 23(1), 104. https://doi.org/10.1186/s13054-019-2378-9
8. Timsit, J., Bassetti, M., Cremer, O., Daikos, G., De Waele, J., Kallil, A., Kipnis, E., Kollef, M., Laupland, K., Paiva, J., Rodríguez-Baño, J., Ruppé, É., Salluh, J., Taccone, F. S., Weiss, E., & Barbier, F. (2019). Rationalizing antimicrobial therapy in the ICU: a narrative review. Intensive Care Medicine, 45(2), 172–189. https://doi.org/10.1007/s00134-019-05520-5
9. Kaboli, P. J., Hoth, A. B., McClimon, B. J., & Schnipper, J. L. (2006). Clinical pharmacists and inpatient medical care. Archives of Internal Medicine, 166(9), 955. https://doi.org/10.1001/archinte.166.9.955
10. Kopp, B. J., Erstad, B. L., Allen, M. E., Theodorou, A. A., & Priestley, G. (2006). Medication errors and adverse drug events in an intensive care unit: Direct observation approach for detection. Critical Care Medicine, 34(2), 415–425. https://doi.org/10.1097/01.ccm.0000198106.54306.d7
11. Tamma PD, Holmes A, Ashley ED. Antimicrobial stewardship: another focus for patient safety. Curr Opin Infect Dis. 2014;27(4):348–55
12. Falcone M, Russo A, Gentiloni Silveri N. Role of the clinical pharmacist in antimicrobial stewardship and infection control. Clin Microbiol Infect. 2020;26(6):698–703.
13. Lodise TP, Patel N, Lomaestro BM. Relationship between initial vancomycin trough concentration and nephrotoxicity. Antimicrob Agents Chemother. 2009;53(7):2836–42.
14. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock. Intensive Care Med. 2017;43(3):304–77.